Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copper Cu 64 PSMA I&T PET/CT for Nodal Staging in Newly Diagnosed Prostate Cancer
2024-512754-16-01Phase 3Completed
- Sponsor
- Curium
- Start
- Jan 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Positron Emitters → Radiopharmaceuticals
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of copper Cu 64 PSMA I&T in prostate cancer (PCa), sponsored by Curium. Primary endpoints: Sensitivity of copper Cu 64 PSMA I&T PET/CT for metastatic pelvic lymph node detection and Specificity of copper Cu 64 PSMA I&T PET/CT for absence of metastatic pelvic lymph nodes. Started Jan 2025; status: completed.
02
Drugs
copper Cu 64 PSMA I&T
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2024-512754-16-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512754-16-01.